Group 1 - Jizhi Co., Ltd. plans to acquire at least 51% equity in Pumai Technology through cash payment, aiming to gain control over the company, which is a leading enterprise in the field of robot performance testing and calibration in China [1] - Yaxing Chemical's subsidiary intends to transfer 7.14% equity for 60 million yuan to another fund under the same control, indicating strategic investment movements within the same management group [2] - Weigao Bio's application for clinical trials of subcutaneous human immunoglobulin has been accepted by the National Medical Products Administration, targeting primary immunodeficiency diseases [3] Group 2 - Sentai Co., Ltd.'s controlling shareholder plans to increase shareholding by at least 100 million yuan within 12 months, aiming to enhance confidence in the company's future [4] - Health元's subsidiary has received acceptance for the marketing authorization application of Lecanemab injection, which is intended for moderate to severe plaque psoriasis patients [5][11] - Sunshine Nuohuo has signed a technical development contract for the STC008 injection project, with a total payment of 500 million yuan, indicating significant investment in cancer treatment [6] Group 3 - Hunan YN has been designated as a delivery warehouse for lithium carbonate by the Guangzhou Futures Exchange, enhancing its position in the lithium market [7] - Tianji Co., Ltd. is pushing for the industrialization of lithium sulfide material preparation, although it faces risks in commercialization [8] - Yuandong Bio has received FDA approval for Methylene Blue injection, expanding its product portfolio in the U.S. market [10] Group 4 - Nanshan Aluminum has established a wholly-owned subsidiary in Hainan with an investment of 5 million yuan, focusing on high-end aluminum products [13] - ST Xifa plans to acquire 50% equity in Lhasa Beer, aiming for full ownership, with the transaction currently in the planning stage [14] - Hengrui Medicine's SHR-A1904 injection has been included in the list of breakthrough therapy products, indicating its potential in treating advanced gastric cancer [12] Group 5 - Chengdu Gas is planning to merge three subsidiaries, streamlining operations and enhancing efficiency [26] - Baoli Electric intends to invest 50 million yuan to establish a wholly-owned subsidiary focused on key equipment and solutions in energy storage [27] - Huadian International has successfully put the second unit of its Longkou Phase IV project into commercial operation, marking a significant milestone in its energy production capacity [34]

瑞舒伐他汀依折麦布片主要用于治疗高胆固醇血症以及纯合子家族性高胆固醇血症（HoFH）。依折麦 布与瑞舒伐他汀钙两药联合可协同增效，能增加降血脂疗效并降低心血管事件。 人民财讯12月24日电，中国医药（600056）12月24日公告，下属全资子公司天方药业（600253）收到国 家药品监督管理局核准签发的瑞舒伐他汀依折麦布片（I）《药品注册证书》。 ...

中国医药公告称，下属全资子公司天方药业收到国家药监局核准签发的瑞舒伐他汀依折麦布片（I） 《药品注册证书》，剂型为片剂，规格为每片含瑞舒伐他汀钙10mg与依折麦布10mg，生产企业为山东 朗诺制药有限公司。截至公告披露日，该药品累计投入约2439万元。2024年中国三大终端六大市场该药 品销售额约146万元（仅原研），2025年前三季度约2353万元。此次获批利于丰富产品线、积累经验， 但药品销售或不达预期。 ...